Segment, Geographical and Other Revenue Information - Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Segment Reporting Information [Line Items]
Total revenues	$ 14,967	$ 12,319	$ 29,637	$ 27,901
Cost of product revenue	1,699	2,772	4,240	7,163
Research and development	10,853	8,274	21,820	16,290
Selling, general and administrative	8,522	7,896	17,512	16,311
Total costs and operating expenses	21,074	18,942	43,572	39,764
Income (loss) from operations	(6,107)	(6,623)	(13,935)	(11,863)
Depreciation and amortization			(900)	(693)
Income (loss) before income taxes	(6,037)	(6,491)	(13,684)	(11,624)
Stock-based compensation	1,939	1,988	4,108	4,051
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	7,506	10,589	18,379	20,676
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	7,461	1,730	11,258	7,225
Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	14,967	12,319	29,637	27,901
Cost of product revenue	1,699	2,772	4,240	7,163
Research and development	10,487	7,990	21,108	15,748
Selling, general and administrative	2,996	2,923	5,933	5,541
Total costs and operating expenses	15,182	13,685	31,281	28,452
Income (loss) from operations	(215)	(1,366)	(1,644)	(551)
Stock-based compensation	1,939	1,988	4,108	4,051
Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	7,506	10,589	18,379	20,676
Cost of product revenue	1,699	2,772	4,240	7,163
Research and development	4,997	5,134	10,693	9,576
Selling, general and administrative	2,375	2,362	4,720	4,463
Total costs and operating expenses	9,071	10,268	19,653	21,202
Income (loss) from operations	(1,565)	321	(1,274)	(526)
Stock-based compensation	741	601	1,496	1,237
Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	7,461	1,730	11,258	7,225
Research and development	5,490	2,856	10,415	6,172
Selling, general and administrative	621	561	1,213	1,078
Total costs and operating expenses	6,111	3,417	11,628	7,250
Income (loss) from operations	1,350	(1,687)	(370)	(25)
Stock-based compensation	252	197	494	338
Corporate [Member]
Segment Reporting Information [Line Items]
Total costs and operating expenses	(5,316)	(4,698)	(11,042)	(10,271)
Depreciation and amortization	(506)	(427)	(998)	(802)
Income (loss) before income taxes	(6,037)	(6,491)	(13,684)	(11,624)
Stock-based compensation	946	1,190	2,118	2,476
Product Sales [Member]
Segment Reporting Information [Line Items]
Total revenues	4,504	6,249	9,604	14,236
Product Sales [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	4,504	6,249	9,604	14,236
Product Sales [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	0	0	0	0
Product Sales [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	4,504	6,249	9,604	14,236
Product Sales [Member] | Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	4,504	6,249	9,604	14,236
Research and Development Revenue [Member]
Segment Reporting Information [Line Items]
Total revenues	10,463	6,070	20,033	13,665
Research and Development Revenue [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	3,002	4,340	8,775	6,440
Research and Development Revenue [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	7,461	1,730	11,258	7,225
Research and Development Revenue [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Total revenues	10,463	6,070	20,033	13,665
Research and Development Revenue [Member] | Operating Segments [Member] | Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Total revenues	3,002	4,340	8,775	6,440
Research and Development Revenue [Member] | Operating Segments [Member] | Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Total revenues	$ 7,461	$ 1,730	$ 11,258	$ 7,225